Overview
- Editors:
-
-
Rolf Dinkel
-
HealthEcon Ltd., Basel, Switzerland
-
Bruno Horisberger
-
Interdisciplinary Research Centre for Pulic Health, St. Gallen, Switzerland
-
Kenneth W. Tolo
-
The University of Texas at Austin, Austin, USA
Access this book
Other ways to access
Table of contents (59 papers)
-
Reports and Recommendations from the Working Groups
-
- K. Tolo, D. Taylor, D. Burley
Pages 258-261
-
Ethical Perspectives Revisited
-
Front Matter
Pages 263-263
-
-
-
-
An Agenda for Action
-
Front Matter
Pages 275-275
-
-
- Rolf Dinkel, Bruno Horisberger, Kenneth W. Tolo
Pages 280-287
-
Appendix
-
Front Matter
Pages 289-289
-
- Rolf Dinkel, Bruno Horisberger, Kenneth W. Tolo
Pages 291-315
-
- Rolf Dinkel, Bruno Horisberger, Kenneth W. Tolo
Pages 317-320
-
- Rolf Dinkel, Bruno Horisberger, Kenneth W. Tolo
Pages 321-329
-
- Rolf Dinkel, Bruno Horisberger, Kenneth W. Tolo
Pages 331-332
-
- Rolf Dinkel, Bruno Horisberger, Kenneth W. Tolo
Pages 333-334
-
Back Matter
Pages 335-338
About this book
As the focus on pharmaceuticals has broadened from concern for their cost and effectiveness to their real and potential risks and benefits, a critical question has been raised: whose responsibility is it to improve drug safety? In April 1990, this question became the theme for a conference at Wolfsberg, Switzerland, near the shores of Lake Constance. Called an "international dialogue conference" by its organizers, the meeting brought together leaders from the pharmaceutical industry, regulatory authorities, academia, medicine, consumer organizations and the media. Opening addresses were given by representatives of the Council for International Organizations of Medical Sciences (CIOMS), the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), the Swiss International Pharmaceutical Agency, and the RAD-AR Consortium. This book documents the papers presented and discussions held at this conference, which took the topic of risks and benefits of drug therapy one step further to responsibility. It includes a rich menu of issues for those who care about the evaluation of drug therapy, the ethics behind it, the expectations of the patient, and the role of traditional and nontraditional drug safety communica tions. The ideas expressed here come from different parts of the world but relate to common drug safety problems, observations, and scientific assessments; they provide insights into innovative approaches, cautious changes, and desired actions. The papers in this volume are broadly divided into conceptual perspectives (ethics, how the knowledge about drug risks and benefits is generated and appraised, the expectations in drug safety) and operational perspectives (communication, discussion, and action).
Editors and Affiliations
-
HealthEcon Ltd., Basel, Switzerland
Rolf Dinkel
-
Interdisciplinary Research Centre for Pulic Health, St. Gallen, Switzerland
Bruno Horisberger
-
The University of Texas at Austin, Austin, USA
Kenneth W. Tolo